{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-062103","form_type":"8-K","ticker":"REPL","cik":"0001737953","company_name":"Replimune Group, Inc.","filed_at":"2023-05-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.305178+00:00","generated_at":"2026-06-14T21:21:54.348018+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Replimune reports Q4 FY2023 net loss $49.2M, CFO Franchi resigns, cash $583.4M into H2 2025","bullets":["Q4 net loss $49.2M, FY net loss $174.3M vs $118.0M prior year; R&D spend $126.5M up 59% YoY.","Cash $583.4M as of Mar 31, 2023, providing runway into H2 2025; $311.4M raised in financing during year.","CFO Jean Franchi resigns effective June 2, 2023; consulting through Dec 31, 2023 with $483K severance.","Andrew Schwendenman appointed Chief Accounting Officer; CEO Astley-Sparke serves as interim CFO.","CERPASS topline data expected Q3 2023; BLA submission for RP1 in CSCC planned Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-062103","json":"https://secwatch.observer/filing/0001104659-23-062103.json","markdown":"https://secwatch.observer/filing/0001104659-23-062103.md","text":"https://secwatch.observer/filing/0001104659-23-062103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465923062103/0001104659-23-062103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465923062103/tm2316116d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T21:21:54.348018+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e3022bb06a3d2bd91a9a9e3e46d4e3aa14cc816d","claim":"Replimune Group, Inc. reported financial results for the fourth quarter and year ended March 31, 2023.","evidence_excerpt":"On May 18, 2023, Replimune Group, Inc. (the “Company”) issued a news release announcing its financial results for the fourth quarter and year ended March 31, 2023 and certain corporate updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465923062103/0001104659-23-062103-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"041c68291f","claim":"Jean Franchi resigned as Chief Financial Officer at Replimune Group, Inc..","evidence_excerpt":"Jean Franchi has resigned from her position as the Company’s Chief Financial Officer, effective as of June 2, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465923062103/0001104659-23-062103-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"bf48faeb45","claim":"Andrew Schwendenman was appointed as Chief Accounting Officer at Replimune Group, Inc..","evidence_excerpt":"the Board of Directors of the Company designated Andrew Schwendenman, the Company’s former Vice President of Finance, to serve as the Company’s Chief Accounting Officer effective as of May 18, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465923062103/0001104659-23-062103-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Accounting Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}